Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
(R)-MG132 and Mechanistic Inference
2026-11-12
A cervical-cancer study connects lactate-responsive HNRNPU K181 lactylation with PHGDH-dependent serine metabolism and tumor growth. The low-activity MG-132 stereoisomer belongs to a different evidentiary category: a proteasome-control context that can help separate proteasome-dependent observations from broader chemical or cellular effects, but does not itself establish the lactate–HNRNPU–PHGDH mechanism.
What the HNRNPU Lactylation Evidence Shows
2026-11-12
A critical reading of evidence linking HNRNPU K181 lactylation to PHGDH regulation and cervical cancer metabolism, with particular attention to what a proteasome-control stereoisomer can—and cannot—establish.
What LNP–p53 mRNA Evidence Shows
2026-11-11
A review-level analysis of how lipid nanoparticles are positioned as delivery systems for p53 mRNA and other nucleic-acid cancer therapies, distinguishing mechanistic rationale from demonstrated antitumor evidence.
Interpreting (R)-MG132 in HNRNPU Cancer Research
2026-11-11
The cervical-cancer study supports a lactate–HNRNPU K181–PHGDH axis, whereas (R)-MG132 is best interpreted as a low-activity MG-132 enantiomer used for proteasome-dependence control. These are complementary but not interchangeable evidence streams.
Why Cytosolic crRNAs Matter for Cas13
2026-11-10
A study comparing U1- and U6-driven CRISPR RNAs shows that guide-RNA localization is a major determinant of Cas13 performance in mammalian-cell reporter systems, while leaving important questions about specificity, durability and broader applicability.
HNRNPU Lactylation and Cervical Cancer Metabolism
2026-11-10
A literature-focused analysis of how the cited study connects HNRNPU K181 lactylation with PHGDH RNA regulation, serine metabolism, and cervical cancer growth. It also separates the study’s mechanistic evidence from the distinct control role documented for the MG-132 enantiomer (R)-MG132.
(R)-MG132 and the Limits of Negative Controls
2026-11-09
A critical reading of the cervical-cancer study separates genetic evidence for an HNRNPU–PHGDH metabolic axis from the more confounded pharmacological findings, while defining what a low-activity MG-132 enantiomer can and cannot establish in proteasome-control studies.
When Context Changes a Molecular Result
2026-11-09
A cervical-cancer study shows why the meaning of a molecular result depends on the model, perturbation, comparator, and readout. Its evidence supports a lactate–HNRNPU–PHGDH axis, while pharmacological and proteasome-control contexts support narrower interpretations.
When Context Changes a Proteasome Result
2026-11-08
The meaning of a molecular result depends on the perturbation, comparator, model and readout used to obtain it. This editorial separates the cervical-cancer evidence for HNRNPU K181 lactylation from the interpretive role of (R)-MG132 as a stereochemical proteasome control.
When Context Changes a Molecular Result
2026-11-07
A cervical-cancer study illustrates why molecular results must be interpreted through their model, perturbation, comparator and readout. The findings support an HNRNPU K181 lactylation–PHGDH axis, while (R)-MG132 belongs to a separate proteasome-control context and does not, by itself, establish that metabolic mechanism.
When Context Changes a Molecular Result
2026-11-06
The meaning of a result depends on its model, perturbation, comparator, and readout. The cervical-cancer study connects HNRNPU K181 lactylation to PHGDH regulation and serine metabolism, while (R)-MG132 belongs to a different control logic centered on proteasome dependence. Keeping those contexts separate clarifies what the evidence supports—and what it does not.
HNRNPU Lactylation and Control Logic
2026-11-06
A cervical-cancer study connects lactate-associated HNRNPU K181 lactylation with PHGDH regulation, serine metabolism, and tumor growth. The findings support a mechanistic model, while the broader pharmacology of Pazopanib and the separate role of (R)-MG132 as a proteasome-control material define important interpretive boundaries.
When Context Changes a Scientific Result
2026-11-05
A result acquires meaning from its model, material form, readout, and intended use. Comparing acetoacetate-related metabolic claims with a deuterium-labeling study of degarelix shows why analytical success cannot be transferred automatically into biological or clinical conclusions.
HNRNPU Lactylation and Cervical Cancer Metabolism
2026-11-05
A recent study connects lactate-sensitive HNRNPU K181 lactylation with PHGDH transcript regulation, serine biosynthesis, and cervical cancer growth. Its findings support a mechanistic axis, while the multi-target pharmacology and model limitations require caution when interpreting translational relevance or proteasome-control materials.
When Research Context Changes a Claustrum Result
2026-11-04
A comparative claustrum study shows why gene-expression findings cannot be interpreted apart from species, anatomy, marker selection, and signal-detection context. The analysis distinguishes what Cyanine 3 Tyramide can contribute as a fluorescent readout from what the underlying biological evidence can establish about conserved claustrum organization.